What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
His primary scientific interests are in Melanoma, Internal medicine, Surgery, Oncology and Ipilimumab.
His work carried out in the field of Melanoma brings together such families of science as Cancer and Clinical trial.
His Internal medicine study frequently draws parallels with other fields, such as Gastroenterology.
The study incorporates disciplines such as Cobimetinib and Hazard ratio in addition to Surgery.
In his study, which falls under the umbrella issue of Hazard ratio, Regimen is strongly linked to Placebo.
The Sunitinib research Axel Hauschild does as part of his general Oncology study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma (3248 citations)
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2107 citations)
What are the main themes of his work throughout his whole career to date?
Axel Hauschild mainly focuses on Internal medicine, Melanoma, Oncology, Surgery and Dermatology.
He combines topics linked to Gastroenterology with his work on Internal medicine.
Axel Hauschild has researched Melanoma in several fields, including Cancer, Adjuvant therapy, Ipilimumab and Immunology.
His Oncology research includes themes of Metastatic melanoma, Vemurafenib and Phases of clinical research, Chemotherapy, Dacarbazine.
His Surgery research integrates issues from Adverse effect, Alpha interferon and Hazard ratio.
The Dermatology study combines topics in areas such as Skin cancer and Pathology.
He most often published in these fields:
- Internal medicine (52.34%)
- Melanoma (43.16%)
- Oncology (39.45%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (52.34%)
- Oncology (39.45%)
- Melanoma (43.16%)
In recent papers he was focusing on the following fields of study:
Axel Hauschild spends much of his time researching Internal medicine, Oncology, Melanoma, In patient and Artificial intelligence.
Within one scientific family, Axel Hauschild focuses on topics pertaining to Placebo under Internal medicine, and may sometimes address concerns connected to Hazard ratio.
His Oncology research incorporates themes from Metastatic melanoma, Vemurafenib, Dabrafenib, Clinical trial and Trametinib.
Axel Hauschild focuses mostly in the field of Melanoma, narrowing it down to topics relating to Immune checkpoint inhibitors and, in certain cases, Oncolytic virus and Randomized controlled trial.
His study in Artificial intelligence is interdisciplinary in nature, drawing from both University hospital, Medical diagnosis and Skin cancer.
Axel Hauschild combines subjects such as Targeted therapy and Dacarbazine with his study of Cobimetinib.
Between 2018 and 2021, his most popular works were:
- Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task (114 citations)
- A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. (81 citations)
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. (62 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
Axel Hauschild mostly deals with Internal medicine, Melanoma, Oncology, Artificial intelligence and Skin cancer.
His work is dedicated to discovering how Internal medicine, Placebo are connected with Adjuvant and other disciplines.
His work in Melanoma addresses subjects such as Stage, which are connected to disciplines such as Cutaneous melanoma.
His study looks at the relationship between Oncology and topics such as Survival rate, which overlap with Efficacy and Cancer immunotherapy.
As part of one scientific family, Axel Hauschild deals mainly with the area of Dabrafenib, narrowing it down to issues related to the Trametinib, and often Randomized controlled trial.
His Phases of clinical research study combines topics in areas such as Anti pd 1, Dacarbazine and Monoclonal.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
